简体中文English

ZNF384 (12p13) gene breakage probe reagent
Wholesale Price(RMB):

30006000330066003300660036007200

Product Code:R-0501117Ⅰ-01/R-0501117Ⅰ-02/R-0501117Ⅱ-01/R-0501117Ⅱ-02/R-0501117Ⅲ-01/R-0501117Ⅲ-02/R-0501117Ⅳ-01/R-0501117Ⅳ-02
Probe name:GSP ZNF384(Centromere)/ GSP ZNF384(Telomere)
Product Code:Type I (direct FISH method)/Type II (biotin-labeled indirect FISH method)/Type III (digoxigenin-labeled indirect FISH method)/Type IV (TSA-FISH method)
Registration Number:
Clinical Value

Clinically relevant chromosomal abnormalities such as hyperdiploidy, hypodiploidy, t(12;21), t(1;19), t(9;22), and MLL translocations have been identified in approximately 3/4 of pediatric precursor B-cell ALL (BCP-ALL) patients. These targets play an important role in risk stratification and treatment. However, the pathogenesis and driver genes of the remaining BCP-ALL patients, called “B-others ALL”, are not fully understood.


MEF2D, ZNF384, and DUX4 are new fusion gene subtypes newly identified in “B-others ALL”.


In 2015, a study published in <Leukemia> showed that NGS sequencing of 55 patients without these chromosomal abnormalities identified 2 cases with EP300-ZNF384 fusions. The authors then identified 4 cases of this fusion gene in 346 BCP-ALL cases, none of which were accompanied by the above chromosomal abnormalities.